Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p53 Peptide Vaccine and IL-2 in Advanced Breast or Ovarian Cancer
NCT00019916Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2000
- Modality
- Whole Cell Cancer Vaccines, Peptides, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of p53 peptide-loaded dendritic cell vaccine (University of Pittsburgh) in breast cancer, ovarian cancer, sponsored by National Cancer Institute. Started Jun 2000; status: completed.
02
Drugs
p53 peptide-loaded dendritic cell vaccine (University of Pittsburgh)
03
Conditions
breast cancerovarian cancer
Beyond the preview
Go deeper on NCT00019916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019916.